EC approves AstraZeneca’s Calquence tablet formulation for CLL
23 Feb 2023
Drug ApprovalImmunotherapyPhase 3Phase 1Clinical Result
Preview
Source: Pharmaceutical Technology
The tablet formulation of Calquence received approval to treat chronic lymphocytic leukaemia. Credit: Nephron / Wikimedia.
The European Commission (EC) has granted approval for AstraZeneca’s tablet formulation of Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL) in adult patients.
The selective Bruton’s tyrosine kinase (BTK) inhibitor CalquenceBruton’s tyrosine kinase (BTK) inhibitor Calquence binds covalently to BTK, and then inhibit its activity.
EC’s approval comes after the Committee for Medicinal Products for Human Use’s positive opinion.
It is based on the data obtained from the ELEVATE-PLUS trials, which include three single-dose, open-label, cross-over Phase I trials conducted in 116 healthy participants.
The studies established bioequivalence between acalabrutinib 100mg tablets and acalabrutinib 100mg capsules.
They assessed the proton pump inhibitors (PPI) effect of acalabrutinib tablets given in the presence against the absence of PPI rabeprazole.
Findings demonstrated that the Calquence capsule and tablet formulations are bioequivalent in the trials.
AstraZeneca Oncology Business Unit executive vice-president Dave Fredrickson said: “The Calquence tablet formulation underscores our commitment to understanding the needs of the chronic lymphocytic leukaemia community and providing patient-oriented treatment solutions.
“Today’s approval offers physicians and patients in the EU more flexibility to determine the right treatment plan and enables more patients to potentially benefit from this medicine.”
In the US, Calquence received approval as a capsule and tablet formulation to treat CLL, small lymphocytic lymphoma (SLL) and relapsed or refractory mantle cell lymphoma (MCL) patients.
In a separate development, AstraZeneca has received EC approval for its Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations to treat advanced liver and lung cancers.
The combination of Imfinzi with Imjudo received approval for the first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC) in adult patients.
Imfinzi along with Imjudo and platinum-based chemotherapy, received approval to treat metastatic (Stage IV) non-small cell lung cancer (NSCLC) in these patients.
The two regulatory approvals are based on the data obtained from the Phase III HIMALAYA and POSEIDON trials.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.